Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD1 | P21728 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | HTR1D | P28221 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24010035 | 0.82 | EHMT2 (0.41) | EHMT2 | |
| SCHEMBL25831651 | 0.78 | CHRM3 (0.35) | DRD2DRD1DRD3 | |
| SCHEMBL25461128 | 0.77 | ADAM17 (0.34) | KDM4EALDH1A1HTR1D | |
| SCHEMBL25820234 | 0.77 | HTR2A (0.34) | KDM4EHTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL23999682 | 0.75 | EHMT2 (0.32) | KDM4EEHMT2ALDH1A1HTR1D | |
| SCHEMBL25831641 | 0.67 | EHMT2 (0.38) | EHMT2 | |
| SCHEMBL25821294 | 0.67 | KMT2A (0.33) | KDM4EHTR2AHTR2CHTR2BEHMT2 | |
| SCHEMBL23999684 | 0.65 | ALDH1A1 (0.39) | EHMT2ALDH1A1 | |
| SCHEMBL24006324 | 0.64 | SIGMAR1 (0.41) | HTR2CHTR2BEHMT2HTR1D | |
| SCHEMBL25821292 | 0.63 | TLR9 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | KDM4E 4219/4885HTR2A 2539/4885HTR2C 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.